{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:44:32Z","timestamp":1791575072883,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":862,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41379-020-0553-9","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T17:06:39Z","timestamp":1588007199000},"page":"1773-1782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent"],"prefix":"10.1016","volume":"33","author":[{"given":"Marie Colombe","family":"Agahozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J.","family":"Westenend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-928X","authenticated-orcid":false,"given":"Mieke R.","family":"van Bockstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hansum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Giang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanneke E.","family":"Matlung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien H.M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-020-0553-9_bib1","doi-asserted-by":"crossref","first-page":"e797","DOI":"10.1136\/bmj.e797","article-title":"Ductal carcinoma in situ of the breast How does DCIS develop?","volume":"344","author":"Barnes","year":"2012","journal-title":"BMJ."},{"key":"10.1038\/s41379-020-0553-9_bib2","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","article-title":"Effect of three decades of screening mammography on breast-cancer incidence","volume":"367","author":"Bleyer","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1038\/s41379-020-0553-9_bib3","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1038\/s41379-020-0553-9_bib4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41379-019-0331-8","article-title":"Ductal carcinoma in situ of the breast: immune cell composition according to subtype","volume":"33","author":"Agahozo","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-0553-9_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","article-title":"Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study","volume":"158","author":"Doebar","year":"2016","journal-title":"Breast Cancer Res Treat."},{"key":"10.1038\/s41379-020-0553-9_bib6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41379-018-0030-x","article-title":"Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?","volume":"31","author":"Agahozo","year":"2018","journal-title":"Mod Pathol."},{"key":"10.1038\/s41379-020-0553-9_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/his.12188","article-title":"Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast","volume":"63","author":"Van Bockstal","year":"2013","journal-title":"Histopathology."},{"key":"10.1038\/s41379-020-0553-9_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/annonc\/mdw623","article-title":"The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","volume":"28","author":"Pruneri","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-0553-9_bib9","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","article-title":"Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast","volume":"31","author":"Toss","year":"2018","journal-title":"Mod Pathol."},{"key":"10.1038\/s41379-020-0553-9_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Bre","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1038\/s41379-020-0553-9_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","article-title":"Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast","volume":"161","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res Treat."},{"key":"10.1038\/s41379-020-0553-9_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/modpathol.2015.158","article-title":"The immune microenvironment of breast ductal carcinoma in situ","volume":"29","author":"Thompson","year":"2016","journal-title":"Mod Pathol."},{"key":"10.1038\/s41379-020-0553-9_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1309\/AJCPW4EADZ9BNXXM","article-title":"Regressive change in high-grade ductal carcinoma in situ of the breast: histopathologic spectrum and biologic importance","volume":"144","author":"Wasserman","year":"2015","journal-title":"Am J Clin Pathol."},{"key":"10.1038\/s41379-020-0553-9_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/his.13217","article-title":"Prognostic significance of tumour infiltrating B-lymphocytes in breast ductal carcinoma in situ","volume":"71","author":"Miligy","year":"2017","journal-title":"Histopathology."},{"key":"10.1038\/s41379-020-0553-9_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cam4.715","article-title":"CD8 + tumor-infiltrating lymphocytes contribute to spontaneous \u201chealing\u201d in HER2-positive ductal carcinoma in situ","volume":"5","author":"Morita","year":"2016","journal-title":"Cancer Med."},{"key":"10.1038\/s41379-020-0553-9_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/PAI.0b013e3181a1743a","article-title":"Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications","volume":"17","author":"Chivukula","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"10.1038\/s41379-020-0553-9_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2325\/jbcs.12.140","article-title":"Spontanious \u201chealing\u201d of breast cancer","volume":"12","author":"Horii","year":"2005","journal-title":"Breast Cancer."},{"key":"10.1038\/s41379-020-0553-9_bib18","unstructured":"Dutch Institute for Clinical Auditing. Factsheet Indicatoren NABON Breast Cancer Audit (NBCA) 2017, Leiden, 2017 https:\/\/www.zorginzicht.nl\/bibliotheek\/Borstkanker\/RegisterMeetinstrumentenDocumenten\/Indicatorgids. Accessed 19 Sep 2018."},{"key":"10.1038\/s41379-020-0553-9_bib19","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014."},{"key":"10.1038\/s41379-020-0553-9_bib20","unstructured":"FEDERA. Human Tissue and Medical Research: Code of conduct for responsible use (2011). Rotterdam, 2011 https:\/\/www.federa.org\/sites\/default\/files\/digital_version_first_part_code_of_conduct_in_uk_2011_12092012.pdf. Accessed 12 Sep 2018."},{"key":"10.1038\/s41379-020-0553-9_bib21","doi-asserted-by":"crossref","unstructured":"Mitchell E, Jindal S, Chan T, Narasimhan J, Sivagnanam S, Gray E et al. Loss of myoepithelial calponin\u20101 characterizes high\u2010risk ductal carcinoma in situ cases, which are further stratified by T cell composition. Mol Carcinog. 2020. https:\/\/doi.org\/10.1002\/mc.23171.","DOI":"10.1002\/mc.23171"},{"key":"10.1038\/s41379-020-0553-9_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","article-title":"CD8 + cytotoxic T cell and FOXP3 + regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes","volume":"130","author":"Liu","year":"2011","journal-title":"Breast Cancer Res Treat."},{"key":"10.1038\/s41379-020-0553-9_bib23","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1038\/s41379-020-0553-9_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-010-0987-8","article-title":"An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer","volume":"127","author":"Mahmoud","year":"2011","journal-title":"Breast Cancer Res Treat."},{"key":"10.1038\/s41379-020-0553-9_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/bjc.2012.524","article-title":"Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer","volume":"108","author":"West","year":"2013","journal-title":"Br J Cancer."},{"key":"10.1038\/s41379-020-0553-9_bib26","doi-asserted-by":"crossref","first-page":"djw192","DOI":"10.1093\/jnci\/djw192","article-title":"Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer","volume":"109","author":"Bense","year":"2017","journal-title":"J Natl Cancer Inst."},{"key":"10.1038\/s41379-020-0553-9_bib27","first-page":"1492","article-title":"Regulatory T cells control the switch from in situ to invasive breast cancer","volume":"10","author":"Akkari","year":"2019","journal-title":"Front Immunol."},{"key":"10.1038\/s41379-020-0553-9_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell."},{"key":"10.1038\/s41379-020-0553-9_bib29","doi-asserted-by":"crossref","unstructured":"Castle JC, Uduman M, Pabla S, Stein RB, Buell JS. Mutation-derived neoantigens for cancer immunotherapy. Front Immunol. 2019;10:1856.","DOI":"10.3389\/fimmu.2019.01856"},{"key":"10.1038\/s41379-020-0553-9_bib30","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/annonc\/mdx253","article-title":"Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?","volume":"28","author":"Van Bockstal","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1038\/s41379-020-0553-9_bib31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ctrv.2012.04.011","article-title":"The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer","volume":"38","author":"Mohammed","year":"2012","journal-title":"Cancer Treat Rev."},{"key":"10.1038\/s41379-020-0553-9_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41379-019-0367-9","article-title":"Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study","volume":"33","author":"Dano","year":"2019","journal-title":"Mod Pathol."}],"updated-by":[{"DOI":"10.1038\/s41379-020-00707-4","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000}}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0553-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222007062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222007062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T19:35:03Z","timestamp":1722800103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222007062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0893395222007062"],"URL":"https:\/\/doi.org\/10.1038\/s41379-020-0553-9","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/s41379-020-00707-4","asserted-by":"object"}]},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-0553-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-00707-4","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}